ArticleClinical science (London, England : 1979)2025
Serum proteomics links the cardiorespiratory biomarkers CTRC, OSM, and MMP-10 to exacerbation severity and number in patients with COPD.
Article in Clinical science (London, England : 1979), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comorbidity of chronic obstructive pulmonary disease and pulmonary tuberculosis: a bibliometric analysis (2011-2025) with narrative review.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During exacerbations, patients with chronic obstructive pulmonary disease (COPD) are at risk for severe cardiovascular disease (CVD). Despite this, the available literature on systemic biomarkers of CVD during exacerbations is limited. In the present study, a proteomic approach was used to assess alterations in the concentrations of 177 biomarkers of CVD and inflammation in serum samples from 26 long-term smokers (LTS) with mild-to-severe COPD (GOLD stage 1-3) and chronic bronchitis (COPD-CB) but no allergy. These patients were followed for 60 weeks, and they all provided paired samples during stable disease and exacerbations. Serum samples from ten healthy non-smokers (HNS) and ten LTS without COPD or CB constituted controls. Of all the proteins analyzed, only chymotrypsin C (CTRC), oncostatin M (OSM), and matrix metalloproteinase 10 (MMP-10) displayed significantly altered concentrations during exacerbations in the COPD-CB group. Here, the concentrations of CTRC and OSM correlated with exacerbation severity, CRP, blood leukocytes, and other cardiovascular biomarkers. In contrast, the concentration of MMP-10 during stable disease correlated with blood eosinophil counts and exacerbation numbers. Finally, the concentrations of OSM and MMP-10 during stable disease correlated with blood leukocytes and tobacco load, respectively. Our study suggests that CTRC, OSM, and MMP-10 bear potential as cardiorespiratory biomarkers in patients with COPD and CB. Collectively, these biomarkers display substantial alterations during exacerbations and correlate with the severity and number of exacerbations. These results motivate prospective studies to determine the clinical utility of CTRC, OSM, and MMP-10 in assessing cardiorespiratory risk in patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.